OK so an injection every 3 d...not bad. $350-500/ mo sound on the high end, so let us assume she would like to change over to Afrezza , How much would it cost?
Curious...how much does it cost for the Insulin ? why did she not get an insulin pump?
After many years watching Bio Techs...I have noted the companies that put out a lot of announcements tend to put out worthless FLUFF. The companies that are more conservative with their announcements tend to put out REAL NEWS with GREAT IMPACT.
A Full Fib retracement that will drop the price to $8.50....thats it. They will many pennies....meanwhile risking thousands. Tic tock.....
Sooner or later this company will find a Partner...many Big Pharm companies need new products and technology. I wouldn't bet the house on that short position.
Acadia (ACAD) Updates Increase Visibility, Piper Jaffray Says
Article Stock Quotes (1) Comments (0)
Piper Jaffray analyst Charles Duncan, PhD reiterated an Overweight rating and $42 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) saying incremental updates increase regulatory and commercialization visibility.
What is a " incremental updates "?....it might be like a Cat Treat...instead of the whole mouse.
This is very low volume downward move so far. but it cracked our best support level. Someone is making some very stupid @ market price sells and a few shorts are taking this op to cover at the low price. Who the heck is selling like a FOOL. whom ever you are ...YOU ARE A MORON.
Look for a continuation of this drop tomorrow ?, but sooner or later this week the buyers will pick it back up. It needs to close above $10.30.
All stocks retrace, so if you believe it could do a Full Fib Retracement of 61%, ( i used approx numbers of $6.60 as a low to $ 11.50 as a high, (just a quick look at the chart so don't tell me it should $11.27 etc ) it could see Approx $8.50. But I don't believe it will do a Full fib. Probably less. Just showing what those numbers are.
Not short, Not Long. But I find this stock in a unique place and since I am long ACAD I want to use this experience to get a feel how ACAD might respond when it files its NDA. I have posted my thoughts on MNKD, some interesting discussions. I wish no harm and to all good luck. but i will call out the weakness and the strength as i see it as i do on the ACAD MB.
I don't think the street see's Afrezza as a major "break though " drug. If it did this stock should have cracked the resistance at $10.30 and well on its way to $15-20+. But its not. The company has a few negative fundamentals too, High debt, low cash, High OS and a drug with a lot of competition from all those generics and a Black Box Warning which gave investors the initial pause. Also the last failed inhaled insulin left a bad taste. No pun intended. This company needs a PARTNER BADLY. NOW.
Thanks for that point. But my post is about the protocol that insurance companies will use to reimburse the cost of the drug. Learn how to argue. BTW I just thought of another use for inhaled insulin...Recurrent MRSA skin infections. I had several severe DM 1 patients with this problem over and over again with the skin abscesses. An inhaled insulin could really help cut down on those infections.
Address your concerns to my post, WHAT PROTOCOL WILL BE USED. it has nothing to do with a successful commercial roll out. But down the road it could turn out to disappointed sales numbers. Hint- when the numbers come out and the company gives some types of excuses and blames other conditions. Its time to SELL. I have already said the stock will rise in the long term so you can consider that we both agree on that.
But for now with no news after the stock has gone up so much it might be a bumpy ride for those who recently bought on the news....( Buy the rumor...Sell the news ). Look at the RSI ( money coming in or out of the stock)....Down Down Down....
Insurance companies will have a protocol for reimbursement. They always do with new Brand Name drugs. What will drug insurance carries use as a protocol for coverage of this new drug? Keep in mind there are so many treatments available for DM 1& 2. Pills (many kinds), insulin injectables -many kinds with mixtures and now with the pens you can take everywhere that have very tiny needles you hardly feel. Patients love their pens. Which patients will be allowed to use this new drug when there are so many choices available at generic prices.I can see an insurance company allowing inhaled insulin for say special circumstance, eg, a stroke patient with Hx DM 1 or 1&2, ( who can not inject him/herself) at home where the care taker can not give an injection either...say an elderly husband or wife with limited help. If in a SNF
( nursing home), giving injections is usually not a problem. Perhaps if on high INR range blood thinners, to avoid excessive bruising might be another indication for inhaled insulin, but the small needle pens still might be used. There is always the patients that demands the latest treatment...they got the coin and don't care if its not a covered drug benefit and are willing to pay out of pocket. So there are a few cases where inhaled insulin could be used.I thought of another use for the inhaled insulin...low vision/blindness. But i don't think "needle phobia " will be good enough for coverage of inhaled insulin unless it is a valid Diagnosis already confirmed by a mental health provider and documented in the patients record. Afrezza is going to cost a ton of money compared to any generic DM 1 or 2 drugs. Consider they have to pass the cost on to their members. They ALREADY charge separate CO-PAYS - low for generic drugs and about 7-10 times HIGHER for Brand name drugs. Will Medicare just say...yeah go ahead and use a high cost brand name drug even if a generic works? i doubt it. There will be protocols...there always are.
Type Value Conf.
resist. 30.10 2
resist. 28.78 2
resist. 25.34 3
resist. 24.88 2
resist. 24.33 2
resist. 23.82 3
supp 22.50 13
supp 21.50 2
supp 20.98 3
supp 20.05 7
supp 19.15 2
supp 17.88 4